Europe
Event provides a perfect partnering platform to exchange with industry executives and to look for novel approaches to fight antimicrobial resistance
Artios Pharma Limited, The University of Texas MD Anderson Cancer Center and ShangPharma Innovation announce the in-licensing by Artios of a small-molecule ATR inhibitor programme, developed jointly by MD Anderson and ShangPharma.
The arrival of patient-centric CDMO’s predicted by CPhI Annual Report
Four new ZEISS Axiocam models are introduced for light microscopy applications
Takeda will unload a portfolio of over-the-counter and prescription pharmaceutical products to Germany-based STADA for $660 million as the company continues to pare down debt from its $62 billion acquisition of Shire.
Vifor picks up external R&D capabilities for its own nephrology pipeline and Evotec gains a commercial partner via outlicensing all kidney disease assets that are developed from the joint venture.
AstraZeneca is significantly expanding its footprint in China with the establishment of a global research and development center in the country, as well as the launch of a $1 billion fund aimed at supporting that nation’s healthcare sector.
Researchers at Sweden’s Karolinska Institutet identified 10 potential drug targets for glioblastoma and published the results in the journal Cell Reports.
LNC Therapeutics, a French biotech company specializing in gut microbiome-based drug research and discovery, announced formation of its Scientific Advisory Board, composed of preeminent experts in the gut microbiome and related therapeutic applications.
Eveliqure Biotechnologies announces the grant of a Wellcome Trust Innovator Award that supports the early clinical development of its Shigella-ETEC combination vaccine with ~£500K and complements the previously secured ~€11 million funding from public sources for the vaccine’s development
PRESS RELEASES